This site is intended for health professionals only
Revenue continued to rise in 2008 driven primarily by Lundbeck’s products Cipralex (18% increase), Ebixa (14% increase) and Azilect (57% increase). Europe reported the strongest growth rate of 13% (14% at constant exchange rates), with Cipralex, Ebixa and Azilect continuing to win market shares. In the International Markets segment, revenue was up 10% (17% at constant exchange rates) driven especially by sales of Cipralex, which consistently won market shares throughout the year. In the USA, revenue was impacted by a reduction of Lexapro inventories, which pushed down revenue by DKK 256 million. Net of this reduction, Lexapro revenue would have increased by 5%.
In connection with the annual report, Lundbeck’s President and CEO Ulf Wiinberg says: “In 2008, our financial performance was highly satisfactory and showed strong growth. Our ambition is for Lundbeck to be the company that makes the biggest difference worldwide in the treatment of patients suffering from central nervous system disorders. Lundbeck is to be a growth company and the upcoming takeover of Ovation and the in house initiatives we have launched at Lundbeck provide us with a good starting point for accomplishing that ambition – during the period 2012-14 as well.”
For more information, visit: Lundbeck